Adial Pharmaceuticals Inc Cash Flow-to-Debt Ratio
Adial Pharmaceuticals Inc cash flow-to-debt ratio. Adial Pharmaceuticals Inc (ADIL) has a Cash Flow-to-Debt Ratio of -0.22x as of June 2026, meaning its operating cash flow of $-6.36 Million could theoretically repay 0% of its total liabilities ($28.93 Million) in one year. See financial flexibility index of Adial Pharmaceuticals Inc to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Adial Pharmaceuticals Inc (2015–2025)
Cash flow-to-debt ratio of Adial Pharmaceuticals Inc from 2015 to 2025. Historical debt coverage capacity for Adial Pharmaceuticals Inc across 11 annual periods. Also explore net asset growth rate of Adial Pharmaceuticals Inc to track the company's year-over-year net asset growth rate.
Adial Pharmaceuticals Inc Cash Flow-to-Debt Ratio by Year (2015–2025)
Adial Pharmaceuticals Inc cash flow-to-debt ratio by year from 2015 to 2025. Year-by-year debt coverage analysis for Adial Pharmaceuticals Inc. For the full cash flow conversion analysis, see Adial Pharmaceuticals Inc (ADIL) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.27x | $-6.49 Million | $1.52 Million | ▲ +39.9% |
| 2024 | -7.09x | $-6.92 Million | $975.86K | ▲ +31.9% |
| 2023 | -10.42x | $-6.81 Million | $653.51K | ▼ -128.7% |
| 2022 | -4.55x | $-11.19 Million | $2.46 Million | ▼ -57.2% |
| 2021 | -2.90x | $-11.95 Million | $4.13 Million | ▲ +42.9% |
| 2020 | -5.07x | $-7.63 Million | $1.51 Million | ▲ +56.9% |
| 2019 | -11.76x | $-6.34 Million | $539.05K | ▼ -21.4% |
| 2018 | -9.68x | $-2.50 Million | $257.97K | ▼ -1919.9% |
| 2017 | -0.48x | $-494.86K | $1.03 Million | ▲ +55.4% |
| 2016 | -1.08x | $-274.38K | $255.02K | ▲ +87.7% |
| 2015 | -8.76x | $-465.22K | $53.08K | — |